SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2021 / NephroSant, Inc., a kidney well being spin out of UC San Francisco, immediately introduced it has closed its oversubscribed Sequence A funding spherical of $16 million. DaVita Venture Group led the funding spherical, with participation from DigitalDx Ventures and different earlier buyers. The funding can be used to assist analysis and growth and the launch of NephroSant’s first product: Qsant™, a needle-free urine check that helps decide if a affected person’s physique is rejecting a transplanted kidney.
“We’re very excited in regards to the alternative to work with DaVita, a acknowledged chief in kidney care,” stated Dr. Minnie Sarwal, CEO and founding father of NephroSant, in addition to Professor of Surgical procedure at UCSF. “Their experience and expertise present the right complement to the imaginative and prescient and focus of NephroSant to redefine kidney well being.”
Qsant™ is the primary home-based urine check designed particularly for the detection of kidney transplant rejection, with out the necessity for a pricey and invasive biopsy. This check makes use of a number of biomarkers together with a proprietary expertise for measurement of urine cell-free DNA. At the moment, as much as 40% of all kidney transplant recipients lead to medical or sub-clinical rejection. Figuring out and predicting rejection earlier will allow clinicians to intervene sooner and assist sufferers dwell an extended life.
“Reworking kidney care requires daring innovation, which is exactly why DaVita Enterprise Group invested in NephroSant and its game-changing resolution that helps sufferers handle their transplanted kidney well being,” stated Dr. Jeff Giullian, Chief Medical Officer for DaVita. “As a transplant nephrologist, I sit up for a future the place sufferers not solely have better entry to a transplant but additionally can lengthen the lifetime of a transplant with Qsant™.”
By giving the affected person the choice of an in-home pattern assortment technique, Qsant™ enhances affected person comfort and security, particularly essential within the present COVID-19 pandemic. Furthermore, Qsant™ requires a single urine void as an alternative of a 24-hour urine assortment. Qsant™ makes use of a proprietary-based algorithm to generate a quantitative rejection threat distinctive for every affected person, known as the affected person’s personalised “Q-Rating.“
“As Nephrosant’s first institutional investor, we’re honored to welcome DaVita Enterprise Group and comply with them into this subsequent spherical of funding,” shared Michele Colucci, founder and Managing Associate for DigitalDx Ventures. “Dr. Minnie Sarwal’s non-invasive urine exams for kidney well being and transplant rejection are revolutionary, combining a patient-centric strategy and distinctive accuracy. We’re very lucky to have the ability to assist this unbelievable feminine founder and play an integral position on the board as we pursue our mission to make high quality healthcare extra accessible to all.”
NephroSant is a fast-paced diagnostic startup based by physicians, with a staff of world-class scientists, engineers and clinicians, centered on making use of the founding staff’s years of medical analysis experience to enhance world kidney well being. Our mission is to translate the deep scientific and pathological insights into best-in-class noninvasive exams to handle the hidden epidemic of power kidney illness, which impacts greater than 10% of the world’s grownup inhabitants, via a rising pipeline of merchandise. Nephrosant was spun out of the Sarwal Lab, UCSF. To be taught extra, go to nephrosant.com.
About DaVita Inc.
DaVita (NYSE:DVA) is a well being care supplier centered on reworking care supply to enhance high quality of life for sufferers globally. The corporate is without doubt one of the largest suppliers of kidney care companies within the U.S. and has been a pacesetter in medical high quality and innovation for greater than 20 years. Via DaVita Kidney Care, the corporate treats sufferers with power kidney failure and end-stage kidney illness. DaVita is dedicated to daring, patient-centric care fashions, implementing the newest applied sciences and transferring towards built-in care choices for all. Via these efforts, DaVita has additionally change into the biggest supplier of house dialysis within the nation. As of Dec. 31, 2020, DaVita served 204,200 sufferers at 2,816 outpatient dialysis facilities in america. The corporate additionally operated 321 outpatient dialysis facilities in 10 nations worldwide. DaVita has diminished hospitalizations, improved mortality, and labored collaboratively to propel the kidney care trade to undertake an equitable and high-quality commonplace of take care of all sufferers, all over the place. To be taught extra, go to DaVita.com/About.
View supply model on accesswire.com: